Skip to main content

Table 1 Baseline characteristics of the study population according to the TyG index

From: The synergistic effect of the triglyceride-glucose index and serum uric acid on the prediction of major adverse cardiovascular events after coronary artery bypass grafting: a multicenter retrospective cohort study

Variables

All (n = 1225)

TyG ≤ 8.87 (n = 774)

TyG > 8.87 (n = 451)

P-value

General conditions

 Age (years)

62.79 ± 8.18

63.16 ± 8.22

62.12 ± 8.08

0.032

 Male, n (%)

857 (70.0)

569 (73.5)

288 (63.9)

< 0.001

 BMI (kg/m2)

25.67 ± 3.58

25.42 ± 3.64

26.11 ± 3.43

0.001

 LVEF (%)

58.12 ± 10.52

58.46 ± 10.30

57.54 ± 10.88

0.142

 Previous MI, n (%)

259 (21.1)

154 (19.9)

105 (23.3)

0.162

 Previous stroke, n (%)

185 (15.1)

104 (13.4)

81 (18.0)

0.033

 Previous PCI, n (%)

122 (10.0)

80 (10.3)

42 (9.3)

0.564

 Left main disease, n (%)

282 (23.0)

171 (22.1)

111 (24.6)

0.312

 Multivessel disease, n (%)

1147 (93.6)

710 (91.7)

437 (96.9)

< 0.001

Risk factors, n (%)

 Current smoking

339 (27.7)

207 (26.7)

132 (29.3)

0.341

 Current drinking

316 (25.8)

199 (25.7)

117 (25.9)

0.929

 FH-CHD

247 (20.2)

145 (18.7)

102 (22.6)

0.102

 DM

395 (32.2)

164 (21.2)

231 (51.2)

< 0.001

 Hypertension

767 (62.6)

451 (58.3)

316 (70.1)

< 0.001

 Hyperlipidemia

394 (32.2)

215 (27.8)

179 (39.7)

< 0.001

Surgical procedure

 Duration of surgery (min)

270.00 (240.00–310.00)

270.00 (240.00–306.25)

270.00 (240.00–315.00)

0.425

 OPCABG, n (%)

139 (11.3)

75 (9.7)

64 (14.2)

0.017

 Number of grafts

3.60 ± 0.98

3.56 ± 0.99

3.65 ± 0.96

0.134

 Use of arterial grafts, n (%)

1171 (95.6)

738 (95.3)

433 (96.0)

0.587

Laboratory tests

 FPG (mmol/L)

5.41 (4.77–6.84)

4.99 (4.56–5.66)

6.97 (5.57–9.20)

< 0.001

 TC (mmol/L)

4.10 (3.48–4.96)

3.90 (3.30–4.62)

4.56 (3.78–5.18)

< 0.001

 TG (mmol/L)

1.32 (0.99–1.77)

1.08 (0.86–1.34)

1.95 (1.56–2.60)

< 0.001

 LDL-C (mmol/L)

2.45 (1.92–3.04)

2.36 (1.85–2.86)

2.66 (2.13–3.34)

< 0.001

 HDL-C (mmol/L)

1.12 ± 0.26

1.14 ± 0.27

1.08 ± 0.24

< 0.001

 eGFR (mL/min/1.73 m2)

107.38 ± 29.59

107.42 ± 31.04

107.40 ± 26.97

0.990

 SUA (μmol/L)

307.00 (258.50–372.00)

304.00 (257.00–363.00)

317.00 (262.00–383.00)

0.013

Medications at the time of discharge, n (%)

 Antiplatelet drugs

1214 (99.1)

768 (99.2)

446 (98.9)

0.777

 Statins

1023 (83.5)

652 (84.2)

371 (82.3)

0.369

 Fibrates

83 (6.8)

38 (4.9)

45 (10.0)

0.001

 Hypoglycemic drugs

285 (23.3)

117 (15.1)

168 (37.3)

< 0.001

 Urate-lowering drugs

14 (1.1)

7 (0.9)

7 (1.6)

0.304

EuroSCORE II

1.45 (1.00–2.41)

1.43 (1.00–2.44)

1.47 (0.99–2.36)

0.822

MACE, n (%)

263 (21.5)

118 (15.2)

145 (32.2)

< 0.001

  1. TyG index triglyceride-glucose index, BMI body mass index, LVEF left ventricle ejection fraction, MI myocardial infarction, PCI percutaneous coronary intervention, FH-CHD family history of coronary heart disease, DM diabetes mellitus, OPCABG off-pump coronary artery bypass grafting, FPG fasting plasma glucose, TC total cholesterol, TG triglyceride, LDL-C low-density lipoprotein-cholesterol, HDL-C high-density lipoprotein-cholesterol, eGFR estimated glomerular filtration rate, SUA serum uric acid, EuroSCORE European System for Cardiac Operative Risk Evaluation score, MACE major adverse cardiovascular event